Vanguard Group
ZBIO

Vanguard Group’s Zenas BioPharma ZBIO Stock Holding History

Vanguard Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$52.8M Buy
1,453,065
+290,307
+25% +$9.55M ﹤0.01% 2135
2025
Q3 		$25.8M Buy
1,162,758
+170,546
+17% +$2.78M ﹤0.01% 2498
2025
Q2 		$9.61M Buy
992,212
+16,306
+2% +$159K ﹤0.01% 2924
2025
Q1 		$7.71M Sell
975,906
-3,417
-0.3% -$26.7K ﹤0.01% 2986
2024
Q4 		$8.02M Buy
979,323
+829,323
+553% +$12.9M ﹤0.01% 3065
2024
Q3 		$2.54M Buy
+150,000
New +$2.7M ﹤0.01% 3485

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group's ZBIO Position: Q4 2025 in Review

Vanguard Group increased its Zenas BioPharma (ZBIO) stake by 25% in Q4 2025, buying an estimated $9.55M and bringing the position to 1,453,065 shares worth $52.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2135.

Vanguard Group first reported a position in ZBIO in Q3 2024 and has held it in 6 quarters since. 118 funds tracked by Wall St. Rank hold ZBIO as of Q4 2025.

  • Vanguard Group held 1,453,065 shares of Zenas BioPharma worth $52.8M as of Q4 2025.
  • Vanguard Group bought 290,307 Zenas BioPharma shares in Q4 2025, an estimated $9.55M.
  • Zenas BioPharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2135 holding.
  • Vanguard Group first reported a position in Zenas BioPharma in Q3 2024 and has held it in 6 quarters since.
  • 118 funds tracked by Wall St. Rank held Zenas BioPharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.